Who makes tranexamic acid Oral-Long Arm?

tranexamic acid Oral-Long Arm is developed by Rush University Medical Center.

What development phase is tranexamic acid Oral-Long Arm in?

tranexamic acid Oral-Long Arm is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

tranexamic acid Oral-Long Arm

Rush University Medical Center · FDA-approved active Small molecule Quality 0/100

Tranexamic acid Oral-Long Arm, marketed by Rush University Medical Center, is an established product in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and market presence, which provides a solid foundation for continued revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	tranexamic acid Oral-Long Arm
Sponsor	Rush University Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Oral Tranexamic Acid After Total Knee Arthroplasty (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

tranexamic acid Oral-Long Arm CI brief — competitive landscape report
tranexamic acid Oral-Long Arm updates RSS · CI watch RSS
Rush University Medical Center portfolio CI